Reni Benjamin
Stock Analyst at JMP Securities
(1.57)
# 3,349
Out of 4,898 analysts
194
Total ratings
42.24%
Success rate
-10.8%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Downgrades: Market Perform | n/a | $129.36 | - | 22 | Jun 3, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $22.96 | - | 10 | May 15, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $26 → $22 | $8.08 | +172.28% | 14 | May 2, 2025 | |
| CUE Cue Biopharma | Reiterates: Market Outperform | $2 | $0.78 | +157.40% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $0.40 | +150.63% | 9 | Mar 31, 2025 | |
| ALLO Allogene Therapeutics | Upgrades: Market Outperform | $5 | $1.29 | +287.60% | 7 | Mar 14, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $70.00 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $0.78 | - | 5 | Mar 7, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $1.29 | +210.08% | 5 | Jan 14, 2025 | |
| CGEN Compugen | Maintains: Market Outperform | $8 → $4 | $1.59 | +151.57% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $2.73 | - | 4 | Nov 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.15 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $7.08 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $16 | $0.28 | +5,593.95% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $18.68 | -46.47% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $4.22 | +18.48% | 6 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $6.35 | +340.94% | 11 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $24.49 | - | 2 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $25.40 | +57.48% | 4 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $1.48 | - | 7 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.01 | - | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $0.82 | +388.40% | 5 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.76 | - | 10 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $8.45 | -5.33% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $54.00 | +11.11% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $8.31 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $224.76 | +40.15% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $93.89 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $225.79 | +17.37% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $3.43 | +395.63% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.33 | - | 3 | Nov 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $8.70 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $1.58 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $38.92 | -69.17% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $14.49 | - | 1 | Nov 15, 2017 |
Blueprint Medicines
Jun 3, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $129.36
Upside: -
Inhibrx Biosciences
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $22.96
Upside: -
Bicycle Therapeutics
May 2, 2025
Maintains: Market Outperform
Price Target: $26 → $22
Current: $8.08
Upside: +172.28%
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $2
Current: $0.78
Upside: +157.40%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $0.40
Upside: +150.63%
Allogene Therapeutics
Mar 14, 2025
Upgrades: Market Outperform
Price Target: $5
Current: $1.29
Upside: +287.60%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $70.00
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.78
Upside: -
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $1.29
Upside: +210.08%
Compugen
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.59
Upside: +151.57%
Nov 12, 2020
Upgrades: Market Perform
Price Target: n/a
Current: $2.73
Upside: -
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.15
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $7.08
Upside: -
Oct 22, 2018
Maintains: Outperform
Price Target: $20 → $16
Current: $0.28
Upside: +5,593.95%
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $18.68
Upside: -46.47%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $4.22
Upside: +18.48%
Jun 4, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $6.35
Upside: +340.94%
Jun 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $24.49
Upside: -
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $25.40
Upside: +57.48%
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $1.48
Upside: -
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.01
Upside: -
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $0.82
Upside: +388.40%
Mar 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.76
Upside: -
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $8.45
Upside: -5.33%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $54.00
Upside: +11.11%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $8.31
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $224.76
Upside: +40.15%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $93.89
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $225.79
Upside: +17.37%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $3.43
Upside: +395.63%
Nov 15, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $0.33
Upside: -
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $8.70
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $1.58
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $38.92
Upside: -69.17%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $14.49
Upside: -